Literature DB >> 8977752

The assessment of growth hormone status in normal young adult males using a variety of provocative agents.

A Rahim1, A A Toogood, S M Shalet.   

Abstract

OBJECTIVE: In adults, there are few data regarding GH responses to provocative stimuli other than insulin-induced hypoglycaemia. We have compared the GH response to four different growth hormone secretagogues and placebo in normal healthy adult males.
DESIGN: This was a prospective, randomized, placebo-controlled study in 18 normal male subjects. After an overnight last, an intravenous cannula was inserted into the arm of each subject and a blood sample was taken for GH at -30, -15, and 0 minutes. Four provocative agents (intravenous insulin 0.2 IU/kg; intravenous arginine 20 g/m2 as an infusion over 30 minutes; oral clonidine, either 100 or 200 micrograms; intramuscular glucagon 1 mg) and placebo were administered to each subject in a randomized manner on different days. Further blood samples were taken at 15-minute intervals for 180 minutes for GH estimation.
RESULTS: The median (range) GH peak response for each agent was insulin 107.7 (28.1-200) mU/l; arginine 22.3 (3.1-72.9) mU/l; glucagon 42 (11.8-200) mU/l; 100 micrograms clonidine 7.2 (< 1-22.2) mU/l; 200 micrograms clonidine 8.2 (1.1- 88) mU/l and placebo 2.4 (< 1-30.2) mU/l. The peak GH response to insulin-induced hypoglycaemia (ITT) was significantly greater than for any other agent (P < 0.0001). The peak GH response to glucagon was significantly greater than for arginine (P < 0.05), clonidine at 100 and 200 micrograms (P < 0.01) and placebo (P < 0.01). The peak GH response following administration of arginine was significantly greater than for clonidine 100 and 200 micrograms (P < 0.05), and placebo (P < 0.01). The peak GH response following clonidine 200 micrograms was not significantly greater than following clonidine 100 micrograms (P = 0.38) or placebo. On an individual basis two, six and 15 of 18 subjects failed to achieve a peak GH level of > 20 mU/l to glucagon, arginine and clonidine respectively. In complete contrast only one subject achieved a peak response of less than 40 mU/l (28.1 mU/l) to ITT.
CONCLUSIONS: The most profound GH release is seen after insulin-induced hypoglycaemia. Glucagon appears to be more effective at inducing GH release than arginine. Clonidine at a dose of 100 or 200 micrograms is no more effective than placebo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977752     DOI: 10.1046/j.1365-2265.1996.00855.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  17 in total

Review 1.  Diagnosis of adult growth hormone deficiency: still a matter of debate.

Authors:  F Camanni
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

Review 2.  Growth hormone secretagogues as diagnostic tools in disease states.

Authors:  R Baldelli; X L Otero; J P Camiña; O Gualillo; V Popovic; C Dieguez; F F Casanueva
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  An evidence-base for laboratory endocrinology?

Authors:  Julian H Barth
Journal:  Clin Biochem Rev       Date:  2008-08

4.  Can a glucagon stimulation test characterized by lower GH cut-off value be used for the diagnosis of growth hormone deficiency in adults?

Authors:  Halit Diri; Zuleyha Karaca; Yasin Simsek; Fatih Tanriverdi; Kursad Unluhizarci; Ahmet Selcuklu; Fahrettin Kelestimur
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

Review 5.  Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.

Authors:  E Ghigo; G Aimaretti; E Arvat; F Camanni
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

6.  Prospective investigation of anterior pituitary function in the acute phase and 12 months after pediatric traumatic brain injury.

Authors:  Halil Ulutabanca; Nihal Hatipoglu; Fatih Tanriverdi; Abdülkerim Gökoglu; Mehmet Keskin; Ahmet Selcuklu; Selim Kurtoglu; Fahrettin Kelestimur
Journal:  Childs Nerv Syst       Date:  2013-12-10       Impact factor: 1.475

7.  Glucagon administration elicits blunted GH but exaggerated ACTH response in obesity.

Authors:  F Tassone; S Grottoli; R Rossetto; B Maccagno; C Gauna; R Giordano; E Ghigo; M Maccario
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

8.  Glucagon stimulation test for the diagnosis of GH deficiency in adults.

Authors:  F L Conceição; A da Costa e Silva; A J Leal Costa; M Vaisman
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

9.  Growth hormone and cortisol secretion in the elderly evaluated using the glucagon stimulation test.

Authors:  Ana Beatriz Winter Tavares; Ignácio Antônio Seixas-da-Silva; Diego H S Silvestre; Maria Fernanda Castelar Pinheiro; Mario Vaisman; Flávia Lucia Conceição
Journal:  Endocrine       Date:  2017-03-11       Impact factor: 3.633

Review 10.  Preoperative assessment for pituitary surgery.

Authors:  Olivia Pereira; John S Bevan
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.